EAU 2017 - Prostate Cancer - Results from #40

Viewing 41-60 of 87 articles

EAU 2017: The diverse genomic landscape of low-risk prostate cancer

EAU 2017: Prostate cancer screening in high risk families: Should PSA testing be performed yearly in first degree relatives with baseline PSA ≤1ng/ml?

EAU 2017: Malignancies in male BRCA mutation carriers – results from a prospectively screened cohort of patients enrolled to a dedicated male BRCA clinic

EAU 2017: At what age should a PSA-based screening program start? 20-year results from the Göteborg randomized population-based prostate cancer screening study

EAU 2017: An evaluation of a selective prostate cancer screening program using family history as a supplementary screening tool to PSA: Results from the ProtecT trial

EAU 2017: APACHE: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab (D, MEDI4736), alone or in combination with Tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)

EAU 2017: Phase 1b/2 trial of pembrolizumab combination therapy for metastatic castration-resistant prostate cancer (mCRPC)

EAU 2017: Does imaging improve safety and efficacy of primary and salvage radiotherapy?

EAU 2017: When and how to include MRI into active surveillance protocols?

EAU 2017: Controversies - Focal therapy and the concept of the index lesion: Nonsense

EAU 2017: Controversies - Focal therapy and the concept of the index lesion: Sense

EAU 2017: EANM Lecture: Is Choline PET Outdated?

EAU 2017: PSMA at Initial Staging

EAU 2017: How to define ‘significant’ disease on targeted biopsy

EAU 2017: Controversies: What helps more to characterize the disease? Biomarkers and Genetic Profiling

EAU 2017: Controversies: What helps more to characterize the disease? Imaging

EAU 2017: Controversies in prostate cancer detection: Biparametric MRI is enough

EAU 2017: Controversies in prostate cancer detection: Multiparametric MRI is a must

EAU 2017: Debate on prostate cancer surgery: radical prostatectomy should be performed with robot - Con

EAU 2017: The argument for surgical management of high-risk prostate cancer

1
2
3
4
5